Please Wait...

Todd Kisner

Main profile

Todd Kisner
Todd Kisner
Vice President, Quality & Regulatory Affairs

Todd Kisner is a recognized clinical research industry senior executive with more than 20 years of experience in the pharmaceutical and technical industries. As the Vice President, Quality Assurance and Regulatory Compliance, he oversees the Corporate Quality Management System, Regulatory Compliance and Records Management groups at Bioclinica. He holds responsibility for ensuring Bioclinica and its products and services comply with international regulatory standards, industry best-practices and leads retrospective oversight activities. Todd has held numerous positions of increasing responsibility and joined Bioclinica as the Vice President of Quality and Regulatory Affairs in 2013. Prior to joining the Company he was responsible for Quality Assurance and Regulatory Compliance with CoreLab Partners and the Director of Quality Assurance with Medifacts International. Todd has held key validation and technical roles at SAS Institute and Thomson Reuters. Additionally he has been a contributor to the Metrics Champion Consortium for both ECG and Imaging, and has extensive experience in data privacy regulation, 21 CFR Part 11, GxP, Quality Assurance, SDLC and Validation Services. He holds an organizational excellence ASQ certification and sits on industry Global Data Protection and Privacy Committees, Ethics & Regulatory Compliance Committees, and GCP Quality Management System work streams.

Blogs

Many questions still remain several years after the July 2012 ODAC (Oncologic Drug Advisory Committee) Meeting on the "Evaluation of Radiologic Review of Progression-free Survival in Non-Hematologic Malignancies." Further investigation was recommended into the utility of taking an audit approach (central reads of a test sample) to identify potential bias in the local evaluation (LE) of patient

Webinars

December 31, 2019 - 12:00pm (EST)

Join this webinar to understand why and what regulatory elements should be considered even before you design your protocol and how this early adoption can lead to shorter, more successful clinical trials and smoother agency submission. Provided case studies will highlight benefits of having expert regulatory guidance, use of compliant processes mirroring FDA guidance and imaging standardization. Imaging charters, more complex Phase 3 and retrospective study considerations will be discussed.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Removing Risk from #ClinicalTrial Management System (CTMS) Implementations @bioclinica https://t.co/EfuSVMSL13
bioclinica (5 hours ago)
Our Research Dev. Director Marieke Cajal in a poster presentation at #CNS Summit showed, "How to Scale up Recruitme… https://t.co/ySQpGIjvt9
bioclinica (5 hours ago)
Great advice on imaging in #clinicaltrials! https://t.co/adsP8h99Ic
bioclinica (3 days ago)
https://t.co/UZQTot9ovJ
bioclinica (3 days ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (3 days ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (3 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices